C4 Therapeutics
Yahoo Finance • 11 months ago
11 Hot Healthcare Stocks To Buy Now
In this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of dai... Full story
Yahoo Finance • 11 months ago
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc. Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma Activity and Im... Full story
Yahoo Finance • 12 months ago
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • last year
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • last year
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader CFT8634, a BRD9 Degrader, Will Not Advance in Synovial Sarcoma and SMARCB1-Null Tumors Due to Insufficient Single... Full story
Yahoo Finance • last year
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma
CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023 CFT7455 Monotherapy Phase 1 Dose Escalation Complete in Relapsed/Refractory Multiple Myeloma; Data to be Pre... Full story
Yahoo Finance • last year
C4 Therapeutics Announces Chief Financial Officer Succession
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-... Full story
Yahoo Finance • last year
12 Best High Risk Penny Stocks to Buy Now
In this article, we will take a look at the 12 best high risk penny stocks to buy now. To see more such companies, go directly to 5 Best High Risk Penny Stocks to Buy Now. Investors are jubilant over Nvidia crushing analyst estimates in i... Full story
Yahoo Finance • last year
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • last year
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science to develop a new generation of s... Full story
Yahoo Finance • last year
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 Phase 1/2 Clinical Trial of CFT1946, a BRAF V600 BiDAC Degrader, E... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-m... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation IND Clearance Achieved for CFT1946, a BRAF-V600 BiDAC Degrader; O... Full story
Yahoo Finance • 2 years ago
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial– – Phase 1/2 Clinical Trial for CFT8634, a BRD9 Degrader, Enrolling Patients and Progressing Through Phase 1 Dose Escalation – – I... Full story
